Scientists discuss the progress made in induced pluripotent stem cells (iPSC)-derived T cells and provides a roadmap for the development of CAR iPSC-derived T cells and off-the-shelf T-iPSCs.
[Pharmaceutical Research]
6445212
XD3SPZS5
items
1
apa
0
default
asc
1
163403
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-e1ef35d62f5f96dd31db10904bca1980%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22XD3SPZS5%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sadeqi%20Nezhad%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-10%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESadeqi%20Nezhad%2C%20M.%2C%20Abdollahpour-Alitappeh%2C%20M.%2C%20Rezaei%2C%20B.%2C%20Yazdanifar%2C%20M.%2C%20%26amp%3B%20Seifalian%2C%20A.%20M.%20%282021%29.%20Induced%20Pluripotent%20Stem%20Cells%20%28iPSCs%29%20Provide%20a%20Potentially%20Unlimited%20T%20Cell%20Source%20for%20CAR-T%20Cell%20Development%20and%20Off-the-Shelf%20Products.%20%3Ci%3EPharmaceutical%20Research%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11095-021-03067-z%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11095-021-03067-z%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DXD3SPZS5%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Induced%20Pluripotent%20Stem%20Cells%20%28iPSCs%29%20Provide%20a%20Potentially%20Unlimited%20T%20Cell%20Source%20for%20CAR-T%20Cell%20Development%20and%20Off-the-Shelf%20Products%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammad%22%2C%22lastName%22%3A%22Sadeqi%20Nezhad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meghdad%22%2C%22lastName%22%3A%22Abdollahpour-Alitappeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Behzad%22%2C%22lastName%22%3A%22Rezaei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahboubeh%22%2C%22lastName%22%3A%22Yazdanifar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%20Marcus%22%2C%22lastName%22%3A%22Seifalian%22%7D%5D%2C%22abstractNote%22%3A%22Chimeric%20antigen%20receptor%20T%20%28CAR-T%29%20cell%20therapy%20has%20been%20increasingly%20conducted%20for%20cancer%20patients%20in%20clinical%20settings.%20Progress%20in%20this%20therapeutic%20approach%20is%20hampered%20by%20the%20lack%20of%20a%20solid%20manufacturing%20process%2C%20T%20lymphocytes%2C%20and%20tumor-specific%20antigens.%20T%20cell%20source%20used%20in%20CAR-T%20cell%20therapy%20is%20derived%20predominantly%20from%20the%20patient%5Cu2019s%20own%20T%20lymphocytes%2C%20which%20makes%20this%20approach%20impracticable%20to%20patients%20with%20progressive%20diseases%20and%20T%20leukemia.%20The%20generation%20of%20autologous%20CAR-T%20cells%20is%20time-consuming%20due%20to%20the%20lack%20of%20readily%20available%20T%20lymphocytes%20and%20is%20not%20applicable%20for%20third-party%20patients.%20Pluripotent%20stem%20cells%2C%20such%20as%20human%20induced%20pluripotent%20stem%20cells%20%28hiPSCs%29%2C%20can%20provide%20an%20unlimited%20T%20cell%20source%20for%20CAR-T%20cell%20development%20with%20the%20potential%20of%20generating%20off-the-shelf%20T%20cell%20products.%20T-iPSCs%20%28iPSC-derived%20T%20cells%29%20are%20phenotypically%20defined%2C%20expandable%2C%20and%20as%20functional%20as%20physiological%20T%20cells.%20The%20combination%20of%20iPSC%20and%20CAR%20technologies%20provides%20an%20exciting%20opportunity%20to%20oncology%20and%20greatly%20facilitates%20cell-based%20therapy%20for%20cancer%20patients.%20However%2C%20T-iPSCs%2C%20in%20combination%20with%20CARs%2C%20are%20at%20the%20early%20stage%20of%20development%20and%20need%20further%20pre-clinical%20and%20clinical%20studies.%20This%20review%20will%20critically%20discuss%20the%20progress%20made%20in%20iPSC-derived%20T%20cells%20and%20provides%20a%20roadmap%20for%20the%20development%20of%20CAR%20iPSC-derived%20T%20cells%20and%20off-the-shelf%20T-iPSCs.%22%2C%22date%22%3A%222021-06-10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs11095-021-03067-z%22%2C%22ISSN%22%3A%221573-904X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11095-021-03067-z%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-11T23%3A29%3A39Z%22%7D%7D%5D%7D
Sadeqi Nezhad, M., Abdollahpour-Alitappeh, M., Rezaei, B., Yazdanifar, M., & Seifalian, A. M. (2021). Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products. Pharmaceutical Research. https://doi.org/10.1007/s11095-021-03067-z Cite
